Vanguard Group Inc Mirati Therapeutics, Inc. Transaction History

Vanguard Group Inc

  • $5.46 Trillion
  • Q3 2024

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$41.99 - $62.38 $16.5 Million - $24.5 Million
-392,939 Reduced 6.89%
5,306,693 $312 Million
Q3 2023

Nov 14, 2023
BUY
$27.8 - $45.35 $20.1 Million - $32.7 Million
721,357 Added 14.49%
5,699,632 $248 Million
Q2 2023

Aug 14, 2023
SELL
$36.13 - $49.49 $2.57 Million - $3.52 Million
-71,100 Reduced 1.41%
4,978,275 $180 Million
Q1 2023

May 15, 2023
BUY
$36.54 - $54.26 $2.76 Million - $4.1 Million
75,487 Added 1.52%
5,049,375 $188 Million
Q4 2022

Feb 10, 2023
BUY
$41.27 - $98.62 $10.1 Million - $24.2 Million
245,589 Added 5.19%
4,973,888 $225 Million
Q3 2022

Nov 14, 2022
BUY
$59.5 - $86.7 $10.7 Million - $15.6 Million
180,278 Added 3.96%
4,728,299 $330 Million
Q2 2022

Aug 12, 2022
BUY
$39.16 - $88.71 $2.55 Million - $5.78 Million
65,211 Added 1.45%
4,548,021 $305 Million
Q1 2022

May 13, 2022
BUY
$75.82 - $150.97 $3.32 Million - $6.62 Million
43,833 Added 0.99%
4,482,810 $369 Million
Q4 2021

Feb 14, 2022
BUY
$132.01 - $190.29 $39.8 Million - $57.3 Million
301,120 Added 7.28%
4,438,977 $651 Million
Q3 2021

Nov 12, 2021
BUY
$132.13 - $177.45 $453,734 - $609,363
3,434 Added 0.08%
4,137,857 $732 Million
Q2 2021

Aug 13, 2021
BUY
$144.0 - $179.73 $595 Million - $743 Million
4,134,423 New
4,134,423 $668 Million

Others Institutions Holding MRTX

# of Institutions
16
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email